# OnCo record destiny-breast04 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/destiny-breast04/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "destiny-breast04", "NCT03734029" ;
  schema:name "DESTINY-Breast04"@en ;
  schema:description "Created a new category of breast cancer, HER2-low, by showing Enhertu works in tumours previously called HER2-negative."@en ;
  schema:url <https://onco.cc/trials/destiny-breast04/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03734029>, <https://doi.org/10.1038/s41591-025-03981-4>, <https://www.nice.org.uk/guidance/ta992> ;
  onco:status "positive" ;
  onco:phase "3" ;
  schema:startDate "2018-12-27" ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/her2-low-metastatic-breast-cancer/>, <https://onco.cc/cancers/tnbc-metastatic/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/topoisomerase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/trastuzumab-deruxtecan/> ;
  onco:companies <https://onco.cc/companies/daiichi-sankyo/>, <https://onco.cc/companies/astrazeneca/> ;
  onco:terms <https://onco.cc/terms/her2-low/> ;
  onco:people <https://onco.cc/people/shanu-modi/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-schettini-her2-low-features-npj-breast-cancer-2021/>, <https://onco.cc/key-papers/paper-destiny-breast04-nejm-2022/>, <https://onco.cc/key-papers/paper-destiny-breast04-nat-med-2025-update/> .